Macropa-NCS |
Catalog No.GC33335 |
Macropa-NCS est conjugué au trastuzumab ainsi qu'au composé RPS-070 ciblant l'antigène membranaire spécifique de la prostate. Un radionucléide thérapeutique prometteur appliqué dans le traitement des métastases des tissus mous.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2146095-31-8
Sample solution is provided at 25 µL, 10mM.
Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070. A promising therapeutic radionuclide applied in the treatment of soft-tissue metastases[1].
[1]. Thiele NA, et al. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14712-14717.
Average Rating: 5
(Based on Reviews and 4 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *